Lincoln Pharma Standalone December 2022 Net Sales at Rs 133.77 crore, up 11.58% Y-o-Y

Lincoln Pharmaceuticals slumped 10.28% to Rs 276.35 after the company reported 12% fall in consolidated net profit to Rs 11.02 crore despite a 29% increase in revenue from operations to Rs 102.58 crore in Q4 FY22 over Q4 FY21.

Lincoln Pharma tumbles after weak Q4 performance

Nandish Shah of HDFC Securities believes that short-term trend of the Nifty is weak. Therefore, his advice is to remain cautious till the Nifty closes above the 17,250 levels.

Hot Stocks | Double-digit Returns From Lincoln Pharma, Globus Spirits, Dalmia Bharat Possible In Short Term. Here’s Why

JMC Projects (India) Ltd, RPSG Ventures Ltd, Lincoln Pharmaceuticals Ltd and Gujarat Fluorochemicals Ltd are among the other gainers in the BSE’s ‘A’ group today, 02 December 2021.

Apex Frozen Foods Ltd leads gainers in ‘A’ group

Lincoln Pharmaceuticals consolidated net profit rises 10.09% in the September 2021 quarter

Eyes Australian market for dermatology, gastro and pain management products

Lincoln Pharma gets Australia’s TGA certification for Gujarat plant

Lincoln Pharmaceuticals on Friday announced that it received approval for the company’s manufacturing facility from Australia’s medicines and medical devices regulator - Therapeutic Goods Administration.

Lincoln Pharma receives approval from Australian Regulator

Company looks to enter the Australian markets soon with its dermatology, gastro and pain management products and gradually expand product portfolio.

Lincoln Pharma gets approval from Australian Regulator

Board of Lincoln Pharmaceuticals approves allotment of 29,728 equity shares

Lincoln Pharma has Excellent Long Term Growth Story but Short Term is Very Jittery

Check out the stocks that will be in focus during trade today based on recent and latest news developments.

Top stocks in focus: Indian Overseas Bank, Ashoka Buildcon, Lincoln Pharma, Persistent Systems, Blue Dart Express

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Financials growth has been moderate for a few years

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is underpriced and is not in the overbought zone

Current price is less than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Lincoln Pharmaceuticals Limited (LPL) is engaged in the business of manufacturing, marketing and distribution of pharmaceutical products.